Liver cancer is the third leading cause of cancer-related deaths worldwide.
In Australia the incidence of hepatocellular carcinoma, the most common form of liver cancer, has consistently risen four to five per cent every year since 1982.
Liver cancer is often diagnosed at a late stage, when treatment options are limited. The current ‘one-size-fits-all’ treatments prolong a patient’s lifespan by only two to three months and are associated with high toxicities. A more detailed understanding of what drives liver cancer at a molecular level is urgently required to personalise treatment and improve prognosis.
The Liver Cancer Collaborative brings together more than 50 multidisciplinary experts in Australia and Asia.
The collaborative aims to build a globally unique biorepository with extensive clinical and genomics data to provide a comprehensive dataset from diagnosis to late-stage disease.
Collaborators include hepatologists, radiologists, pathologists, liver cancer researchers, genomic scientists, computational biologists, immunologists, data and software experts, and consumer representatives.
A comprehensive program of genomic analysis, discovery science, organoid development (lab-grown mini livers) and pre-clinical drug testing is underpinned by the establishment of a world-class liver cancer biobank.
The data will inform a state-of-the-art liver cancer treatment database and a collaborative digital research workspace to help address the growing global challenge of defeating liver cancer.
This multidisciplinary collaboration will:
This rare cancers clinical trial is contributing genomic and clinical data to Minderoo Foundation’s Federated Cancer Data network, which connects harmonised and de-identified cancer patient data, creating a platform to promote global collaborative research.